Monoclonal antibody products have become an important product group in the pharmaceutical industry and are envisioned to make a significant contribution to the next wave of novel therapeutics. Mammalian protein expression technology has been at the core of producing these drugs. While this has been the flagship platform, there continues to be a need for alternate strategies that can decrease both the cost and time of bringing a member of this class of therapeutics to the clinic and ultimately to market. We have developed a robust technology platform for the discovery of novel therapeutic antibodies and the rapid production of full-length humanized antibodies products in Pichia pastoris. This expression system captures all the attributes provided by this host (low cost, strain stability, etc.) while eliminating product development risk associated with untested expression systems. These Pichia produced antibodies display identical biochemical and pharmacokinetic characteristics of conventionally produced antibody proteins. This presentation will outline the strategy and implementation of this platform to support the development ALD 518.